Fasoracetam – Solution
€43.28
Fasoracetam – Solution, 750mg (25mg/mL) Fasoracetam is one of the most scientifically interesting molecules to come out of the “racetam” family — not because it is proven to boost healthy…
Out of stock
This product is currently sold out.
No worries! Enter your email, and we'll let you know as soon as it's back in stock.
In stock
Worldwide Delivery: We ship to most international destinations with tracked services.
Fasoracetam – Solution, 750mg (25mg/mL)
Fasoracetam is one of the most scientifically interesting molecules to come out of the “racetam” family — not because it is proven to boost healthy brains, but because of the ideas it represents. It is a drug with a 35-year history, a genuinely unusual mechanism, and a rare second life in precision medicine: the attempt to match a drug to the specific biology of the people most likely to benefit from it.
This guide explains the science in plain language — what fasoracetam is, how it works, what the evidence shows, and where the genuinely promising threads run.
At a Glance
What it is: A synthetic, water-soluble compound in the racetam family, known across its development history by many research codes: NS-105, NFC-1, AEVI-001, NB-001, and most recently SYN-001. Its international nonproprietary name is fasoracetam.
Why it’s scientifically interesting:
- It modulates all three groups of metabotropic glutamate receptors (mGluRs) — the brain’s slow, regulatory “tuning dials” — with effects that can go in either direction depending on the cell’s state.
- With repeated administration, it increases GABA-B receptors in the rat cortex, pointing to a genuinely novel, non-monoaminergic antidepressant mechanism.
- It enhances cholinergic signaling (acetylcholine release and high-affinity choline uptake) in animal models.
- It is the centerpiece of a precision-psychiatry hypothesis: rather than treating everyone with ADHD or related conditions, treat the subset whose genes point to disrupted glutamate signaling.
Where it stands today:
- Originally tested in Phase 3 trials for vascular dementia (over 1,000 patients) — the program was abandoned for lack of efficacy, though with a good safety record.
- An early, biomarker-selected ADHD study showed significant symptom improvement; larger placebo-controlled trials showed mixed-to-negative primary results but intriguing responder signals.
- The most active current program is in 22q11.2 deletion syndrome (a genetic condition also called DiGeorge syndrome), where a Phase 2 trial met its safety primary endpoint and produced efficacy trends; a Phase 2b is planned.
What Is Fasoracetam ?
Fasoracetam is a small synthetic molecule first synthesized in Japan in the late 1980s. Chemically it belongs to the racetam family — the same broad group as piracetam, aniracetam, and phenylpiracetam — which all share a common two-ring “2-oxopyrrolidine” core and differ mainly in their chemical side chains.
| Property | Detail |
|---|---|
| Molecular formula | C₁₀H₁₆N₂O₂ |
| Molecular weight | ~196.25 g/mol (anhydrous); ~212 g/mol (monohydrate) |
| CAS registry number | 110958-19-5 |
| Chemical class | Racetam (2-oxopyrrolidine derivative) |
| Physical form | White to off-white crystalline powder |
| Solubility | Water-soluble (also soluble in ethanol/DMSO) |
The powder is simply the raw, unformulated chemical — the same molecule that is put into capsules for clinical trials. Being water-soluble distinguishes it from more fat-soluble racetams, and it means the compound dissolves readily in aqueous solutions.
Analogy: Think of the racetams as a family of cars sharing one chassis but with different engines and tuning. Fasoracetam shares the family chassis, but its “tuning” is aimed at the glutamate and GABA systems rather than the same targets as its better-known relatives.
The clinical development form is generally fasoracetam monohydrate — the molecule plus one tightly associated water molecule. That is why some references list a molecular weight around 196 g/mol (the anhydrous molecule) and others around 212 g/mol (the monohydrate). Both describe the same active substance; the difference is only whether the water of crystallization is counted.
A 35-Year Journey: From Dementia Drug to Precision-Medicine Candidate
Few “nootropic-adjacent” compounds have a development history as long or as revealing as fasoracetam’s. It has passed through at least six corporate sponsors and six different code names — a lineage that mirrors the evolution of the science itself.
| Code Name | Sponsor | Era | Indication Pursued | Outcome |
|---|---|---|---|---|
| NS-105 | Nippon Shinyaku (Kyoto, Japan) | late 1980s–1990s | Vascular dementia / cerebrovascular disease | Phase 3 completed; abandoned for lack of efficacy |
| NFC-1 | neuroFix → Medgenics (acquired 2015) | 2014–2016 | mGluR-variant adolescent ADHD | Repurposed under a genetics-based hypothesis |
| AEVI-001 | Aevi Genomic Medicine | 2016–2019 | ADHD (mGluR-selected) | SAGA trend positive; ASCEND missed primary endpoint |
| NB-001 | Nobias Therapeutics | 2021–2026 | 22q11.2 deletion syndrome | Phase 2 met safety; efficacy trends; FDA designations reported |
| SYN-001 | Synaptiq Therapeutics (Iceland) | 2026–present | 22q11.2 deletion syndrome | Phase 2b planned |
The dementia chapter
Developed by Nippon Shinyaku and taken all the way to Phase 3 trials in vascular dementia involving more than 1,000 patients — a scale far beyond most compounds ever called “nootropics” — fasoracetam failed to show sufficient efficacy and was shelved. By some accounts, over $200 million was spent on the program.
The silver lining
The dementia program left behind something valuable: across all those patients, the drug reportedly showed an excellent safety profile with no evidence of addiction potential. That safety legacy is one reason the molecule could later be revived for children and adolescents.
The revival
A team led by genomicist Hakon Hakonarson at the Children’s Hospital of Philadelphia noticed something: some people with ADHD carry rare genetic variations (copy-number variants) in the very glutamate-receptor network that fasoracetam modulates. The idea was radical for its time: don’t give the drug to everyone with ADHD — give it to the genetically defined subset whose glutamate biology is actually disrupted. That hypothesis relaunched a “failed” dementia drug as a candidate for biomarker-selected neuropsychiatry.
Plain-Language Takeaway: A drug can be safe without being effective for one condition, and still be rationally repurposed for a different condition under a completely different hypothesis. Fasoracetam’s story is the poster child for that scientific principle.
The Brain in 60 Seconds
To understand what fasoracetam does, picture the brain as a massive, always-on communication network. Neurons send messages across tiny gaps called synapses using chemical messengers called neurotransmitters, which bind to receptors on the next neuron — like keys fitting into locks.
Three messengers matter most for this story:
- Glutamate — the brain’s main “accelerator.” It excites neurons and drives learning, attention, and alertness.
- GABA (gamma-aminobutyric acid) — the brain’s main “brake.” It calms neural activity and prevents the network from becoming overexcited.
- Acetylcholine — a “highlighter pen” for attention, learning, and memory. It helps the brain decide what to focus on.
The brain needs accelerator and brake in constant balance. Disruptions in glutamate signaling have been linked to ADHD, anxiety, autism-related traits, and more. Fasoracetam is proposed to touch all three systems at once — which is unusual and, mechanistically, quite elegant.
How Fasoracetam Is Thought to Work
Fasoracetam has a distinctive three-part profile. Unlike most ADHD stimulants, it does not appear to act directly on dopamine, serotonin, or noradrenaline. Instead:
1. It modulates all three groups of metabotropic glutamate receptors (mGluRs)
Receptors come in two broad flavors:
- Ionotropic receptors are fast on/off switches — glutamate binds, and the neuron responds almost instantly.
- Metabotropic glutamate receptors (mGluRs) are slower, subtler “tuning dials” that adjust the cell’s internal chemistry and its sensitivity to future signals.
There are eight mGluR subtypes, organized into three groups (I, II, and III), and they can push cellular signaling in different directions. Fasoracetam is notable for having marked activity across all three groups.
This helps explain why its effects are often described as bidirectional or regulatory rather than simply “on” or “off”:
- In some experimental conditions, it dampens a key cellular messenger called cAMP (cyclic AMP).
- In other conditions, it enhances cAMP.
- Both directions can be blocked by mGluR antagonists, and the effects disappear when specific mGluR subtypes are knocked down with antisense DNA — strong evidence that mGluRs are the genuine molecular target.
Analogy: Ionotropic signaling is like pressing a doorbell — instant and binary. Metabotropic signaling is like adjusting a stereo equalizer — it changes the overall sound of the cell rather than a single note. Fasoracetam appears to nudge several equalizer sliders at once, and the direction depends on where the sliders started.
In rat and mouse cortical preparations, fasoracetam inhibited forskolin-stimulated cAMP formation through pertussis-toxin-sensitive G-proteins (Gi), while it enhanced cAMP after those G-proteins were inactivated — implicating Gs. Both effects were blocked by mGluR antagonists, and antisense knockdown of specific mGluR subtypes abolished the inhibition of adenylyl cyclase. Researchers concluded that fasoracetam acts as an activator at mGluR subtypes coupled to adenylate cyclase while acting as an antagonist at subtypes coupled to phosphoinositide hydrolysis. The precise human subtype map remains incomplete.
2. It regulates GABA-B signaling — and the effect depends on timing
GABA-B receptors are a subtype of the brain’s “brake pedal.” Fasoracetam’s relationship with them is time-dependent, which makes it genuinely interesting:
- Acutely: fasoracetam can behave like a GABA-B antagonist — temporarily loosening the brake. Early research showed it reverses the inhibition of cAMP formation caused by the GABA-B agonist baclofen.
- Chronically (repeated administration): in rats, repeated dosing increased the number of GABA-B receptors in the cerebral cortex — without affecting beta-adrenoceptors or 5-HT₂ (serotonin) receptors. More receptors can make the system more sensitive to its own calming GABA signals over time.
Baclofen is a GABA-B agonist whose chronic use tends to downregulate (reduce the number of) its own receptors. The finding that fasoracetam reverses that downregulation — and increases GABA-B receptor numbers on its own — is direct evidence that fasoracetam regulates GABA-B receptor density, not just receptor activity. This is one of the cleaner mechanistic findings in the racetam literature, and it is the basis for the (still unproven in humans) idea that fasoracetam might help restore GABA-B tone after chronic baclofen or similar exposure.
3. It enhances cholinergic signaling (in animals)
The cholinergic system — powered by acetylcholine — is the brain’s “highlighter pen” for attention and memory.
In a comparative animal study, fasoracetam was tested alongside aniracetam, bifemelane, idebenone, and indeloxine in models of cholinergic dysfunction. Fasoracetam showed:
- Antiamnesic activity — it counteracted experimentally induced memory deficits across several models;
- Increased acetylcholine release from the cerebral cortex;
- Increased high-affinity choline uptake (HACU) in both cortex and hippocampus — a marker of ramped-up cholinergic activity;
- Reversal of baclofen-induced memory disruption — linking its GABA effects to memory outcomes.
4. What it notably does not do
This is almost as important as what it does:
- It does not inhibit monoamine uptake (unlike most conventional antidepressants).
- It does not change brain concentrations of monoamines (dopamine, serotonin, noradrenaline) in animal studies.
- It does not bind directly to adrenoceptors, serotonergic, or dopaminergic receptors.
That makes fasoracetam mechanistically orthogonal to stimulants and to standard antidepressants — a different route into attention, mood, and cognition.
| System | Observed Effect | Evidence Level |
|---|---|---|
| mGluRs (groups I–III) | Activation/modulation; bidirectional effects on cAMP | Cell and membrane preparations (rat/mouse cortex) |
| GABA-B receptors | Increased receptor number after repeated dosing; reversal of baclofen-induced downregulation | Rat cortex |
| Cholinergic system | Increased acetylcholine release; increased high-affinity choline uptake; antiamnesic effects | Rat models |
| Monoamine systems | No uptake inhibition; no change in monoamine levels | Rat (in vitro and in vivo) |
The Big Idea: Biomarker-Matched Medicine
The most scientifically exciting part of the fasoracetam story is not the molecule itself — it is the therapeutic strategy it represents.
The genetic discovery
In a large genome-wide study of copy-number variation (CNV), researchers at the Children’s Hospital of Philadelphia found that CNVs affecting metabotropic glutamate receptor genes are enriched in people with ADHD — at a level that survives correction across multiple independent cohorts (P = 2.1 × 10⁻⁹). Specific findings included:
- Deletions in GRM5 (the gene for mGluR5): 10 cases vs. 1 control;
- Deletions in GRM7 and GRM8;
- Duplications in GRM1;
- Roughly 10% of ADHD cases carry rare CNVs in genes that interact with the GRM family network.
In plain terms: for about one in ten people with ADHD, the biology of their condition may involve disrupted glutamate signaling — a “glutamatergic hypofunction” or imbalance.
The hypothesis
This is where fasoracetam gets its second life. The logic runs:
- A meaningful subset of ADHD (and related conditions) involves disrupted mGluR-network signaling.
- Fasoracetam is a modulator of exactly those receptors.
- Therefore, selecting patients by their glutamate-network genetics — rather than treating all-comers — should reveal the drug’s benefit.
This is precision psychiatry: matching the drug to the biology, the way cancer treatments are increasingly matched to tumor genetics.
The proof-of-concept study (2018)
The 2018 study in Nature Communications tested this idea in 30 adolescents (ages 12–17) with ADHD and mutations in mGluR network genes. After a single-blind placebo week, participants received four weeks of escalating doses up to 400 mg twice daily.
The results were genuinely encouraging:
- Global improvement scores (CGI-I) fell from 3.79 at baseline to 2.33 at week 5 (P < 0.001) — a shift from “minimally improved/no change” toward “much improved.”
- Severity scores (CGI-S) fell from 4.83 to 3.86 (P < 0.001).
- The effect was dose-related, with significant benefit first appearing at 100 mg twice daily and strengthening at higher doses.
- The genetic tiering mattered. Patients with the most relevant genetic variants (Tier 1 and Tier 2) improved more than those with more distantly related variants (Tier 3) — consistent with the precision-medicine hypothesis.
- Side effects were generally mild, with no difference in adverse events between the placebo week and active-drug weeks.
Important limitations: the study was open-label after the placebo week (no concurrent placebo group), its primary purpose was safety and pharmacokinetics, and 30 participants is small. Its proper interpretation is proof-of-concept, not proof of efficacy.
Refining the biomarker
Follow-up work went further, proposing that a specific set of genetic markers — CNVs in genes such as CNTN4, GRM8, MC4R, CTNNA2, SNCA, ADRA2A, GRM5, and CA8 — might identify the patients most likely to respond to fasoracetam. This is exactly how a precision-medicine program should work: keep tightening the biomarker until the treatment effect is unambiguous.
Group III mGluRs (mGluR4, 6, 7, 8) sit mainly on the sending side of synapses and act as presynaptic autoreceptors — when activated, they clamp down on glutamate release. In people whose mGluR networks are genetically disrupted, glutamate signaling may be pathologically out of balance. The therapeutic rationale is that enhancing Group III activity could rein in excess glutamate tone — a “rebalancing” rather than a blunt stimulation. This is a hypothesis, but it is a coherent and testable one.
The ADHD Story: Promise Meets Placebo
The precision-medicine hypothesis then met the hardest test in medicine: randomized, double-blind, placebo-controlled trials.
SAGA (Phase 2, 101 adolescents, mGluR-selected)
The SAGA trial compared fasoracetam with placebo in adolescents with ADHD and mGluR-network variants:
- The primary endpoint (ADHD symptom score reduction) was not met — a real disappointment.
- But the secondary signals were notable:
- The inattention subscale showed a strong trend (p = 0.0515 vs. placebo);
- 70% of fasoracetam-treated patients met a predefined “responder” threshold (≥30% symptom improvement), versus 42% on placebo (p = 0.0067);
- 57% were rated “much improved” or “very much improved” on the global clinical scale, versus 33% on placebo (p = 0.0155);
- The drug was well tolerated, with no serious adverse events.
This pattern — a missed primary endpoint with positive responder analyses — is scientifically genuine but weak. It means “there may be something here, especially in subgroups,” not “this drug works.”
ASCEND (Phase 2, Two Parts)
The follow-up ASCEND program tested children and adolescents in two groups — those with mGluR-related variants (Part A) and those without (Part B):
| Trial Part | Population | ADHD Symptom Change (Drug vs. Placebo) | Outcome |
|---|---|---|---|
| Part A | mGluR variant-positive (67 analyzed) | −9.17 vs. −11.34 | Missed primary endpoint (placebo slightly better) |
| Part B | Variant-negative (106 analyzed) | −11.04 vs. −10.38 | Missed primary endpoint |
The honest reading: across the controlled ADHD program, fasoracetam did not reliably separate from placebo. The early open-label signal did not fully reproduce under controlled conditions. In scientific terms, the ADHD hypothesis remains unconfirmed — though subgroup analyses keep the door open.
Open-label studies are prone to expectation effects, regression to the mean, and the natural waxing and waning of symptoms. Placebo-controlled trials exist precisely because they strip these factors out. The gap between fasoracetam’s encouraging 2018 open-label data and its disappointing controlled results is a textbook illustration of why controlled trials matter — and why “promising” must never be confused with “proven.”
The New Frontier: 22q11.2 Deletion Syndrome
The most active — and arguably most promising — current chapter is not ADHD but a rare genetic condition: 22q11.2 deletion syndrome (22q11DS), also known as DiGeorge syndrome.
Why it makes biological sense
22q11DS is caused by a missing segment of chromosome 22. It affects roughly 1 in 4,000 births and carries a high burden of neuropsychiatric symptoms: inattention, anxiety, autism-related social communication difficulties, and elevated risk of psychosis later in life. Crucially, the deleted region contains genes that disrupt glutamate/mGluR network signaling — the very system fasoracetam modulates.
In short: if fasoracetam helps anywhere, it should help in a population whose glutamate network is constitutively disrupted by a known genetic deletion.
The Phase 2 crossover trial (37 children, 2023)
A randomized, double-blind, placebo-controlled crossover trial tested NB-001 (fasoracetam) in 37 children and adolescents (ages 6–17) with molecularly confirmed 22q11DS and clinically significant psychiatric symptoms. Each participant received two 6-week treatment periods (drug and placebo, in random order) separated by a washout.
Key results:
- Primary endpoint met: the drug was safe and well tolerated. The most common adverse events (fatigue, nasopharyngitis) occurred in about 9% of participants; all events were mild to moderate; no serious adverse events were attributed to treatment.
- Efficacy trend: on the Clinical Global Impression–Improvement scale, the drug beat placebo numerically (least-squares mean 3.34 vs. 3.69, p = 0.07). The trial was explicitly not powered to achieve statistical significance on efficacy — it was a signal-finding study.
- Responder rates were 1.4–1.7 times higher with drug than placebo (reported as 40–70% higher).
- Improvement was seen across all three symptom domains — ADHD, anxiety, and autism-related symptoms.
Where it’s heading
The program has continued to move forward:
- The FDA has granted orphan-related designations to fasoracetam monohydrate for 22q11.2 deletion syndrome, reported to include Orphan Drug designation (2024) and Rare Pediatric Disease designation (2026).
- In 2026, Iceland-based Synaptiq Therapeutics acquired the program, renamed NB-001 to SYN-001, and announced plans for a Phase 2b trial in North America and Europe, using a clinical scale developed specifically for 22q11DS.
If a registrational trial eventually succeeds, fasoracetam would become a first-in-class treatment for a condition that currently has no approved drug for its neuropsychiatric symptoms — a genuinely meaningful milestone.
In a crossover design, every participant eventually receives both the drug and the placebo, in random order. Each person serves as their own control, which increases statistical power for a given sample size — useful for rare conditions where recruiting hundreds of patients is hard. The downside is that “carryover” effects (a treatment’s effects lingering into the placebo phase) must be managed, typically with a washout period between phases.
The Antidepressant Angle
A separate and underappreciated thread is fasoracetam’s antidepressant potential — and its mechanism is genuinely novel.
The preclinical evidence
In a 1997 study (Shimidzu et al., European Journal of Pharmacology), fasoracetam (then NS-105) was tested in two classic animal models of depression:
- Forced swim test: animals given fasoracetam (1–100 mg/kg, orally) showed significantly reduced immobility time — an effect similar to that of the standard antidepressant desipramine.
- Learned helplessness test: after exposure to inescapable foot shock, animals normally stop trying to escape. Repeated fasoracetam administration reversed this escape failure.
The interesting part: the mechanism
Most antidepressants work by raising monoamines (serotonin, noradrenaline, dopamine). Fasoracetam does neither:
- It did not inhibit monoamine uptake in vitro.
- It did not change monoamine concentrations in brain tissue or extracellular fluid.
- Instead, repeated administration increased GABA-B receptor numbers in the cerebral cortex — without affecting beta-adrenoceptors or 5-HT₂ receptors.
The authors concluded that fasoracetam has antidepressant-like activity potentially mediated by GABA-B receptor upregulation — a mechanism fundamentally different from SSRIs, SNRIs, or tricyclics.
Why this matters
The GABA-B system has long been implicated in the biology of depression, but few drugs target it the way fasoracetam appears to. A non-monoaminergic antidepressant would be a meaningful addition to a field where many patients don’t respond to current options. Caveat: this is rat data from the 1990s; no human antidepressant trial has established efficacy. The idea is promising, not proven.
How the Body Handles It
Understanding a drug’s pharmacokinetics — how it’s absorbed, distributed, metabolized, and excreted — is essential to understanding its potential.
Absorption and distribution
- In animals, fasoracetam is almost completely absorbed from the small intestine, with very little “first-pass” breakdown by the liver.
- Reported oral bioavailability is high: 79–97% in animals.
- Maximum blood concentrations are reached within about 1 hour (around 30 minutes in rats).
- Protein binding is remarkably low: less than 3.3% in all species tested, including humans. Most of the drug circulates free and available to act — unusual for a small molecule.
Metabolism and elimination
- In animals, fasoracetam is broken down into several metabolites involving modifications of its piperidine ring: LAM-162 (oxidative C–N cleavage), LAM-79 (4-hydroxylation), LAM-163 (3-hydroxylation), plus one unidentified metabolite (M1).
- The drug is excreted mostly unchanged in urine, and clearance tracks kidney function.
- Reported human elimination half-life is roughly 4–6.5 hours (about 5 hours), which is why clinical trials used twice-daily dosing.
Age matters: the 1999 pharmacokinetic study
A study of 14 healthy people — 7 elderly (ages 68–79) and 7 young (ages 20–32) — found clinically relevant differences:
- Peak concentration (Cmax): 3.06 µg/mL (elderly) vs. 2.13 µg/mL (young), p = 0.0117;
- Total exposure (AUC): higher in the elderly;
- Time to peak: longer (2.1 h vs. 1.3 h) and half-life longer;
- Clearance slower in the elderly, attributed to declining kidney function with age.
The authors advised careful observation when the drug is used in older people.
Tissue distribution and pregnancy (animal data)
- In rats, peak tissue concentrations occurred around 30 minutes after dosing; the highest concentrations were found in the kidney and stomach, the lowest in white fat.
- The drug was undetectable in plasma 24 hours after dosing.
- In pregnant rats, fetal concentrations reached up to 66% of maternal blood levels, and the drug transferred into milk at similar concentrations — a clear signal that use during pregnancy and breastfeeding would require extreme caution (and that human data are absent).
- Plasma concentrations did not change with repeated administration in rats — no apparent accumulation or metabolic tolerance — and repeated dosing at 10 mg/kg did not alter hepatic drug-metabolizing enzymes.
Safety: What We Know
Fasoracetam has an unusually large human safety dataset for an experimental compound, but with meaningful gaps.
What the data say
- Across the original Phase 3 dementia program (over 1,000 patients), the drug reportedly showed an excellent safety profile with no evidence of addiction potential.
- In the 2018 ADHD study, the most common side effects were headache, fatigue, upper abdominal pain, diarrhea, irritability, and dizziness — and there was no difference in adverse-event rates between the placebo week and active-drug weeks.
- In the 2023 22q11DS trial, adverse events were mild to moderate, with no serious adverse events attributable to treatment.
- No toxic effects have been clearly attributed to fasoracetam in published studies to date, and animal studies show a low toxicity profile.
Open questions
- Long-term use: no meaningful data exist on months or years of continuous administration in any population.
- Kidney function: since the drug is cleared renally, impaired kidney function would be expected to slow its elimination — relevant given the elderly PK data.
- Combinations: there is a published case report of slow heart rate (bradycardia) after an overdose involving a very large amount of the GABAergic substance phenibut combined with fasoracetam. This does not establish causation by fasoracetam, but it underscores that combining GABA-active or cardiovascular-active substances is uncharted territory.
- Pregnancy and breastfeeding: animal data show substantial fetal and milk transfer; no human safety data exist.
- Interactions: largely unknown. Because fasoracetam influences GABA and acetylcholine signaling, theoretical additive effects with sedatives, alcohol, GABAergic drugs, or cholinergic drugs cannot be excluded.
Chemical Informations
| CAS Number: | 110958-19-5 |
|---|---|
| Purity: | ≥98% |
| Molecular Weight: | 196.25 g/mol |
| Melting Point: | + 57 °C |
| Molecular Formula: | C10H16N2O2 |
| Synonyms: | (5R)-5-oxo-D-prolinepiperidinamide monohydrate, NS-105, AEVI-001, LAM 105, MDGN-001, NFC 1, N-(5-Oxo-D-prolyl)piperidine, UNII-42O8UF5CJB, (R)-1-((5-Oxo-2-pyrrolidinyl)carbonyl)piperidine |
| PubChem CID: | 198695 |
| SMILES: | C1CCN(CC1)C(=O)C2CCC(=O)N2 |
Technical Information:
| Application | Metabotropic Glutamate Receptor Agonist |
| CAS | 110958-19-5 |
| Molar Mass | 196.25 g/mol |
| Chemical Formula | C10H16N2O2 |
| IUPAC Name | (5R)-5-(piperidine-1-carbonyl)pyrrolidin-2-one |
| Synonyms | 5-oxo-D-prolinepiperidinamide monohydrate, NS 105, NS-105, Fasoracetam [INN], NS 105 (pharmaceutical), N-(5-Oxo-D-prolyl)piperidine, UNII-42O8UF5CJB, NS-105, (R)-1-((5-Oxo-2-pyrrolidinyl)carbonyl)piperidine, 42O8UF5CJB, NCGC00182992-01, LAM-105, Piperidine, 1-((5-oxo-2-pyrrolidinyl)carbonyl)-, (R)-, (r)-1-[(5-oxo-2-pyrrolidinyl)carbonyl]piperidine, (+)-1-(((R)-5-Oxo-2-pyrrolidinyl)carbonyl)piperidine, D07WHN, AC1L55VI, DSSTox_CID_28781, DSSTox_RID_83050, CAS-110958-19-5, LS-115850, C13311 |
| Storage | Store at room temperature. Keep tightly sealed, away from heat, light and moisture. |
| Solubility | Soluble in PEG400 |
| Organoleptic Profile | Clear liquid |
| Physical Form | Liquid, solved in PEG400 |
| Specification | 25mg/mL ± 10% |
Fasoracetam – Solution, 750mg (25mg/mL)
Fasoracetam is one of the most scientifically interesting molecules to come out of the “racetam” family — not because it is proven to boost healthy brains, but because of the ideas it represents. It is a drug with a 35-year history, a genuinely unusual mechanism, and a rare second life in precision medicine: the attempt to match a drug to the specific biology of the people most likely to benefit from it.
This guide explains the science in plain language — what fasoracetam is, how it works, what the evidence shows, and where the genuinely promising threads run.
At a Glance
What it is: A synthetic, water-soluble compound in the racetam family, known across its development history by many research codes: NS-105, NFC-1, AEVI-001, NB-001, and most recently SYN-001. Its international nonproprietary name is fasoracetam.
Why it’s scientifically interesting:
- It modulates all three groups of metabotropic glutamate receptors (mGluRs) — the brain’s slow, regulatory “tuning dials” — with effects that can go in either direction depending on the cell’s state.
- With repeated administration, it increases GABA-B receptors in the rat cortex, pointing to a genuinely novel, non-monoaminergic antidepressant mechanism.
- It enhances cholinergic signaling (acetylcholine release and high-affinity choline uptake) in animal models.
- It is the centerpiece of a precision-psychiatry hypothesis: rather than treating everyone with ADHD or related conditions, treat the subset whose genes point to disrupted glutamate signaling.
Where it stands today:
- Originally tested in Phase 3 trials for vascular dementia (over 1,000 patients) — the program was abandoned for lack of efficacy, though with a good safety record.
- An early, biomarker-selected ADHD study showed significant symptom improvement; larger placebo-controlled trials showed mixed-to-negative primary results but intriguing responder signals.
- The most active current program is in 22q11.2 deletion syndrome (a genetic condition also called DiGeorge syndrome), where a Phase 2 trial met its safety primary endpoint and produced efficacy trends; a Phase 2b is planned.
What Is Fasoracetam ?
Fasoracetam is a small synthetic molecule first synthesized in Japan in the late 1980s. Chemically it belongs to the racetam family — the same broad group as piracetam, aniracetam, and phenylpiracetam — which all share a common two-ring “2-oxopyrrolidine” core and differ mainly in their chemical side chains.
| Property | Detail |
|---|---|
| Molecular formula | C₁₀H₁₆N₂O₂ |
| Molecular weight | ~196.25 g/mol (anhydrous); ~212 g/mol (monohydrate) |
| CAS registry number | 110958-19-5 |
| Chemical class | Racetam (2-oxopyrrolidine derivative) |
| Physical form | White to off-white crystalline powder |
| Solubility | Water-soluble (also soluble in ethanol/DMSO) |
The powder is simply the raw, unformulated chemical — the same molecule that is put into capsules for clinical trials. Being water-soluble distinguishes it from more fat-soluble racetams, and it means the compound dissolves readily in aqueous solutions.
Analogy: Think of the racetams as a family of cars sharing one chassis but with different engines and tuning. Fasoracetam shares the family chassis, but its “tuning” is aimed at the glutamate and GABA systems rather than the same targets as its better-known relatives.
The clinical development form is generally fasoracetam monohydrate — the molecule plus one tightly associated water molecule. That is why some references list a molecular weight around 196 g/mol (the anhydrous molecule) and others around 212 g/mol (the monohydrate). Both describe the same active substance; the difference is only whether the water of crystallization is counted.
A 35-Year Journey: From Dementia Drug to Precision-Medicine Candidate
Few “nootropic-adjacent” compounds have a development history as long or as revealing as fasoracetam’s. It has passed through at least six corporate sponsors and six different code names — a lineage that mirrors the evolution of the science itself.
| Code Name | Sponsor | Era | Indication Pursued | Outcome |
|---|---|---|---|---|
| NS-105 | Nippon Shinyaku (Kyoto, Japan) | late 1980s–1990s | Vascular dementia / cerebrovascular disease | Phase 3 completed; abandoned for lack of efficacy |
| NFC-1 | neuroFix → Medgenics (acquired 2015) | 2014–2016 | mGluR-variant adolescent ADHD | Repurposed under a genetics-based hypothesis |
| AEVI-001 | Aevi Genomic Medicine | 2016–2019 | ADHD (mGluR-selected) | SAGA trend positive; ASCEND missed primary endpoint |
| NB-001 | Nobias Therapeutics | 2021–2026 | 22q11.2 deletion syndrome | Phase 2 met safety; efficacy trends; FDA designations reported |
| SYN-001 | Synaptiq Therapeutics (Iceland) | 2026–present | 22q11.2 deletion syndrome | Phase 2b planned |
The dementia chapter
Developed by Nippon Shinyaku and taken all the way to Phase 3 trials in vascular dementia involving more than 1,000 patients — a scale far beyond most compounds ever called “nootropics” — fasoracetam failed to show sufficient efficacy and was shelved. By some accounts, over $200 million was spent on the program.
The silver lining
The dementia program left behind something valuable: across all those patients, the drug reportedly showed an excellent safety profile with no evidence of addiction potential. That safety legacy is one reason the molecule could later be revived for children and adolescents.
The revival
A team led by genomicist Hakon Hakonarson at the Children’s Hospital of Philadelphia noticed something: some people with ADHD carry rare genetic variations (copy-number variants) in the very glutamate-receptor network that fasoracetam modulates. The idea was radical for its time: don’t give the drug to everyone with ADHD — give it to the genetically defined subset whose glutamate biology is actually disrupted. That hypothesis relaunched a “failed” dementia drug as a candidate for biomarker-selected neuropsychiatry.
Plain-Language Takeaway: A drug can be safe without being effective for one condition, and still be rationally repurposed for a different condition under a completely different hypothesis. Fasoracetam’s story is the poster child for that scientific principle.
The Brain in 60 Seconds
To understand what fasoracetam does, picture the brain as a massive, always-on communication network. Neurons send messages across tiny gaps called synapses using chemical messengers called neurotransmitters, which bind to receptors on the next neuron — like keys fitting into locks.
Three messengers matter most for this story:
- Glutamate — the brain’s main “accelerator.” It excites neurons and drives learning, attention, and alertness.
- GABA (gamma-aminobutyric acid) — the brain’s main “brake.” It calms neural activity and prevents the network from becoming overexcited.
- Acetylcholine — a “highlighter pen” for attention, learning, and memory. It helps the brain decide what to focus on.
The brain needs accelerator and brake in constant balance. Disruptions in glutamate signaling have been linked to ADHD, anxiety, autism-related traits, and more. Fasoracetam is proposed to touch all three systems at once — which is unusual and, mechanistically, quite elegant.
How Fasoracetam Is Thought to Work
Fasoracetam has a distinctive three-part profile. Unlike most ADHD stimulants, it does not appear to act directly on dopamine, serotonin, or noradrenaline. Instead:
1. It modulates all three groups of metabotropic glutamate receptors (mGluRs)
Receptors come in two broad flavors:
- Ionotropic receptors are fast on/off switches — glutamate binds, and the neuron responds almost instantly.
- Metabotropic glutamate receptors (mGluRs) are slower, subtler “tuning dials” that adjust the cell’s internal chemistry and its sensitivity to future signals.
There are eight mGluR subtypes, organized into three groups (I, II, and III), and they can push cellular signaling in different directions. Fasoracetam is notable for having marked activity across all three groups.
This helps explain why its effects are often described as bidirectional or regulatory rather than simply “on” or “off”:
- In some experimental conditions, it dampens a key cellular messenger called cAMP (cyclic AMP).
- In other conditions, it enhances cAMP.
- Both directions can be blocked by mGluR antagonists, and the effects disappear when specific mGluR subtypes are knocked down with antisense DNA — strong evidence that mGluRs are the genuine molecular target.
Analogy: Ionotropic signaling is like pressing a doorbell — instant and binary. Metabotropic signaling is like adjusting a stereo equalizer — it changes the overall sound of the cell rather than a single note. Fasoracetam appears to nudge several equalizer sliders at once, and the direction depends on where the sliders started.
In rat and mouse cortical preparations, fasoracetam inhibited forskolin-stimulated cAMP formation through pertussis-toxin-sensitive G-proteins (Gi), while it enhanced cAMP after those G-proteins were inactivated — implicating Gs. Both effects were blocked by mGluR antagonists, and antisense knockdown of specific mGluR subtypes abolished the inhibition of adenylyl cyclase. Researchers concluded that fasoracetam acts as an activator at mGluR subtypes coupled to adenylate cyclase while acting as an antagonist at subtypes coupled to phosphoinositide hydrolysis. The precise human subtype map remains incomplete.
2. It regulates GABA-B signaling — and the effect depends on timing
GABA-B receptors are a subtype of the brain’s “brake pedal.” Fasoracetam’s relationship with them is time-dependent, which makes it genuinely interesting:
- Acutely: fasoracetam can behave like a GABA-B antagonist — temporarily loosening the brake. Early research showed it reverses the inhibition of cAMP formation caused by the GABA-B agonist baclofen.
- Chronically (repeated administration): in rats, repeated dosing increased the number of GABA-B receptors in the cerebral cortex — without affecting beta-adrenoceptors or 5-HT₂ (serotonin) receptors. More receptors can make the system more sensitive to its own calming GABA signals over time.
Baclofen is a GABA-B agonist whose chronic use tends to downregulate (reduce the number of) its own receptors. The finding that fasoracetam reverses that downregulation — and increases GABA-B receptor numbers on its own — is direct evidence that fasoracetam regulates GABA-B receptor density, not just receptor activity. This is one of the cleaner mechanistic findings in the racetam literature, and it is the basis for the (still unproven in humans) idea that fasoracetam might help restore GABA-B tone after chronic baclofen or similar exposure.
3. It enhances cholinergic signaling (in animals)
The cholinergic system — powered by acetylcholine — is the brain’s “highlighter pen” for attention and memory.
In a comparative animal study, fasoracetam was tested alongside aniracetam, bifemelane, idebenone, and indeloxine in models of cholinergic dysfunction. Fasoracetam showed:
- Antiamnesic activity — it counteracted experimentally induced memory deficits across several models;
- Increased acetylcholine release from the cerebral cortex;
- Increased high-affinity choline uptake (HACU) in both cortex and hippocampus — a marker of ramped-up cholinergic activity;
- Reversal of baclofen-induced memory disruption — linking its GABA effects to memory outcomes.
4. What it notably does not do
This is almost as important as what it does:
- It does not inhibit monoamine uptake (unlike most conventional antidepressants).
- It does not change brain concentrations of monoamines (dopamine, serotonin, noradrenaline) in animal studies.
- It does not bind directly to adrenoceptors, serotonergic, or dopaminergic receptors.
That makes fasoracetam mechanistically orthogonal to stimulants and to standard antidepressants — a different route into attention, mood, and cognition.
| System | Observed Effect | Evidence Level |
|---|---|---|
| mGluRs (groups I–III) | Activation/modulation; bidirectional effects on cAMP | Cell and membrane preparations (rat/mouse cortex) |
| GABA-B receptors | Increased receptor number after repeated dosing; reversal of baclofen-induced downregulation | Rat cortex |
| Cholinergic system | Increased acetylcholine release; increased high-affinity choline uptake; antiamnesic effects | Rat models |
| Monoamine systems | No uptake inhibition; no change in monoamine levels | Rat (in vitro and in vivo) |
The Big Idea: Biomarker-Matched Medicine
The most scientifically exciting part of the fasoracetam story is not the molecule itself — it is the therapeutic strategy it represents.
The genetic discovery
In a large genome-wide study of copy-number variation (CNV), researchers at the Children’s Hospital of Philadelphia found that CNVs affecting metabotropic glutamate receptor genes are enriched in people with ADHD — at a level that survives correction across multiple independent cohorts (P = 2.1 × 10⁻⁹). Specific findings included:
- Deletions in GRM5 (the gene for mGluR5): 10 cases vs. 1 control;
- Deletions in GRM7 and GRM8;
- Duplications in GRM1;
- Roughly 10% of ADHD cases carry rare CNVs in genes that interact with the GRM family network.
In plain terms: for about one in ten people with ADHD, the biology of their condition may involve disrupted glutamate signaling — a “glutamatergic hypofunction” or imbalance.
The hypothesis
This is where fasoracetam gets its second life. The logic runs:
- A meaningful subset of ADHD (and related conditions) involves disrupted mGluR-network signaling.
- Fasoracetam is a modulator of exactly those receptors.
- Therefore, selecting patients by their glutamate-network genetics — rather than treating all-comers — should reveal the drug’s benefit.
This is precision psychiatry: matching the drug to the biology, the way cancer treatments are increasingly matched to tumor genetics.
The proof-of-concept study (2018)
The 2018 study in Nature Communications tested this idea in 30 adolescents (ages 12–17) with ADHD and mutations in mGluR network genes. After a single-blind placebo week, participants received four weeks of escalating doses up to 400 mg twice daily.
The results were genuinely encouraging:
- Global improvement scores (CGI-I) fell from 3.79 at baseline to 2.33 at week 5 (P < 0.001) — a shift from “minimally improved/no change” toward “much improved.”
- Severity scores (CGI-S) fell from 4.83 to 3.86 (P < 0.001).
- The effect was dose-related, with significant benefit first appearing at 100 mg twice daily and strengthening at higher doses.
- The genetic tiering mattered. Patients with the most relevant genetic variants (Tier 1 and Tier 2) improved more than those with more distantly related variants (Tier 3) — consistent with the precision-medicine hypothesis.
- Side effects were generally mild, with no difference in adverse events between the placebo week and active-drug weeks.
Important limitations: the study was open-label after the placebo week (no concurrent placebo group), its primary purpose was safety and pharmacokinetics, and 30 participants is small. Its proper interpretation is proof-of-concept, not proof of efficacy.
Refining the biomarker
Follow-up work went further, proposing that a specific set of genetic markers — CNVs in genes such as CNTN4, GRM8, MC4R, CTNNA2, SNCA, ADRA2A, GRM5, and CA8 — might identify the patients most likely to respond to fasoracetam. This is exactly how a precision-medicine program should work: keep tightening the biomarker until the treatment effect is unambiguous.
Group III mGluRs (mGluR4, 6, 7, 8) sit mainly on the sending side of synapses and act as presynaptic autoreceptors — when activated, they clamp down on glutamate release. In people whose mGluR networks are genetically disrupted, glutamate signaling may be pathologically out of balance. The therapeutic rationale is that enhancing Group III activity could rein in excess glutamate tone — a “rebalancing” rather than a blunt stimulation. This is a hypothesis, but it is a coherent and testable one.
The ADHD Story: Promise Meets Placebo
The precision-medicine hypothesis then met the hardest test in medicine: randomized, double-blind, placebo-controlled trials.
SAGA (Phase 2, 101 adolescents, mGluR-selected)
The SAGA trial compared fasoracetam with placebo in adolescents with ADHD and mGluR-network variants:
- The primary endpoint (ADHD symptom score reduction) was not met — a real disappointment.
- But the secondary signals were notable:
- The inattention subscale showed a strong trend (p = 0.0515 vs. placebo);
- 70% of fasoracetam-treated patients met a predefined “responder” threshold (≥30% symptom improvement), versus 42% on placebo (p = 0.0067);
- 57% were rated “much improved” or “very much improved” on the global clinical scale, versus 33% on placebo (p = 0.0155);
- The drug was well tolerated, with no serious adverse events.
This pattern — a missed primary endpoint with positive responder analyses — is scientifically genuine but weak. It means “there may be something here, especially in subgroups,” not “this drug works.”
ASCEND (Phase 2, Two Parts)
The follow-up ASCEND program tested children and adolescents in two groups — those with mGluR-related variants (Part A) and those without (Part B):
| Trial Part | Population | ADHD Symptom Change (Drug vs. Placebo) | Outcome |
|---|---|---|---|
| Part A | mGluR variant-positive (67 analyzed) | −9.17 vs. −11.34 | Missed primary endpoint (placebo slightly better) |
| Part B | Variant-negative (106 analyzed) | −11.04 vs. −10.38 | Missed primary endpoint |
The honest reading: across the controlled ADHD program, fasoracetam did not reliably separate from placebo. The early open-label signal did not fully reproduce under controlled conditions. In scientific terms, the ADHD hypothesis remains unconfirmed — though subgroup analyses keep the door open.
Open-label studies are prone to expectation effects, regression to the mean, and the natural waxing and waning of symptoms. Placebo-controlled trials exist precisely because they strip these factors out. The gap between fasoracetam’s encouraging 2018 open-label data and its disappointing controlled results is a textbook illustration of why controlled trials matter — and why “promising” must never be confused with “proven.”
The New Frontier: 22q11.2 Deletion Syndrome
The most active — and arguably most promising — current chapter is not ADHD but a rare genetic condition: 22q11.2 deletion syndrome (22q11DS), also known as DiGeorge syndrome.
Why it makes biological sense
22q11DS is caused by a missing segment of chromosome 22. It affects roughly 1 in 4,000 births and carries a high burden of neuropsychiatric symptoms: inattention, anxiety, autism-related social communication difficulties, and elevated risk of psychosis later in life. Crucially, the deleted region contains genes that disrupt glutamate/mGluR network signaling — the very system fasoracetam modulates.
In short: if fasoracetam helps anywhere, it should help in a population whose glutamate network is constitutively disrupted by a known genetic deletion.
The Phase 2 crossover trial (37 children, 2023)
A randomized, double-blind, placebo-controlled crossover trial tested NB-001 (fasoracetam) in 37 children and adolescents (ages 6–17) with molecularly confirmed 22q11DS and clinically significant psychiatric symptoms. Each participant received two 6-week treatment periods (drug and placebo, in random order) separated by a washout.
Key results:
- Primary endpoint met: the drug was safe and well tolerated. The most common adverse events (fatigue, nasopharyngitis) occurred in about 9% of participants; all events were mild to moderate; no serious adverse events were attributed to treatment.
- Efficacy trend: on the Clinical Global Impression–Improvement scale, the drug beat placebo numerically (least-squares mean 3.34 vs. 3.69, p = 0.07). The trial was explicitly not powered to achieve statistical significance on efficacy — it was a signal-finding study.
- Responder rates were 1.4–1.7 times higher with drug than placebo (reported as 40–70% higher).
- Improvement was seen across all three symptom domains — ADHD, anxiety, and autism-related symptoms.
Where it’s heading
The program has continued to move forward:
- The FDA has granted orphan-related designations to fasoracetam monohydrate for 22q11.2 deletion syndrome, reported to include Orphan Drug designation (2024) and Rare Pediatric Disease designation (2026).
- In 2026, Iceland-based Synaptiq Therapeutics acquired the program, renamed NB-001 to SYN-001, and announced plans for a Phase 2b trial in North America and Europe, using a clinical scale developed specifically for 22q11DS.
If a registrational trial eventually succeeds, fasoracetam would become a first-in-class treatment for a condition that currently has no approved drug for its neuropsychiatric symptoms — a genuinely meaningful milestone.
In a crossover design, every participant eventually receives both the drug and the placebo, in random order. Each person serves as their own control, which increases statistical power for a given sample size — useful for rare conditions where recruiting hundreds of patients is hard. The downside is that “carryover” effects (a treatment’s effects lingering into the placebo phase) must be managed, typically with a washout period between phases.
The Antidepressant Angle
A separate and underappreciated thread is fasoracetam’s antidepressant potential — and its mechanism is genuinely novel.
The preclinical evidence
In a 1997 study (Shimidzu et al., European Journal of Pharmacology), fasoracetam (then NS-105) was tested in two classic animal models of depression:
- Forced swim test: animals given fasoracetam (1–100 mg/kg, orally) showed significantly reduced immobility time — an effect similar to that of the standard antidepressant desipramine.
- Learned helplessness test: after exposure to inescapable foot shock, animals normally stop trying to escape. Repeated fasoracetam administration reversed this escape failure.
The interesting part: the mechanism
Most antidepressants work by raising monoamines (serotonin, noradrenaline, dopamine). Fasoracetam does neither:
- It did not inhibit monoamine uptake in vitro.
- It did not change monoamine concentrations in brain tissue or extracellular fluid.
- Instead, repeated administration increased GABA-B receptor numbers in the cerebral cortex — without affecting beta-adrenoceptors or 5-HT₂ receptors.
The authors concluded that fasoracetam has antidepressant-like activity potentially mediated by GABA-B receptor upregulation — a mechanism fundamentally different from SSRIs, SNRIs, or tricyclics.
Why this matters
The GABA-B system has long been implicated in the biology of depression, but few drugs target it the way fasoracetam appears to. A non-monoaminergic antidepressant would be a meaningful addition to a field where many patients don’t respond to current options. Caveat: this is rat data from the 1990s; no human antidepressant trial has established efficacy. The idea is promising, not proven.
How the Body Handles It
Understanding a drug’s pharmacokinetics — how it’s absorbed, distributed, metabolized, and excreted — is essential to understanding its potential.
Absorption and distribution
- In animals, fasoracetam is almost completely absorbed from the small intestine, with very little “first-pass” breakdown by the liver.
- Reported oral bioavailability is high: 79–97% in animals.
- Maximum blood concentrations are reached within about 1 hour (around 30 minutes in rats).
- Protein binding is remarkably low: less than 3.3% in all species tested, including humans. Most of the drug circulates free and available to act — unusual for a small molecule.
Metabolism and elimination
- In animals, fasoracetam is broken down into several metabolites involving modifications of its piperidine ring: LAM-162 (oxidative C–N cleavage), LAM-79 (4-hydroxylation), LAM-163 (3-hydroxylation), plus one unidentified metabolite (M1).
- The drug is excreted mostly unchanged in urine, and clearance tracks kidney function.
- Reported human elimination half-life is roughly 4–6.5 hours (about 5 hours), which is why clinical trials used twice-daily dosing.
Age matters: the 1999 pharmacokinetic study
A study of 14 healthy people — 7 elderly (ages 68–79) and 7 young (ages 20–32) — found clinically relevant differences:
- Peak concentration (Cmax): 3.06 µg/mL (elderly) vs. 2.13 µg/mL (young), p = 0.0117;
- Total exposure (AUC): higher in the elderly;
- Time to peak: longer (2.1 h vs. 1.3 h) and half-life longer;
- Clearance slower in the elderly, attributed to declining kidney function with age.
The authors advised careful observation when the drug is used in older people.
Tissue distribution and pregnancy (animal data)
- In rats, peak tissue concentrations occurred around 30 minutes after dosing; the highest concentrations were found in the kidney and stomach, the lowest in white fat.
- The drug was undetectable in plasma 24 hours after dosing.
- In pregnant rats, fetal concentrations reached up to 66% of maternal blood levels, and the drug transferred into milk at similar concentrations — a clear signal that use during pregnancy and breastfeeding would require extreme caution (and that human data are absent).
- Plasma concentrations did not change with repeated administration in rats — no apparent accumulation or metabolic tolerance — and repeated dosing at 10 mg/kg did not alter hepatic drug-metabolizing enzymes.
Safety: What We Know
Fasoracetam has an unusually large human safety dataset for an experimental compound, but with meaningful gaps.
What the data say
- Across the original Phase 3 dementia program (over 1,000 patients), the drug reportedly showed an excellent safety profile with no evidence of addiction potential.
- In the 2018 ADHD study, the most common side effects were headache, fatigue, upper abdominal pain, diarrhea, irritability, and dizziness — and there was no difference in adverse-event rates between the placebo week and active-drug weeks.
- In the 2023 22q11DS trial, adverse events were mild to moderate, with no serious adverse events attributable to treatment.
- No toxic effects have been clearly attributed to fasoracetam in published studies to date, and animal studies show a low toxicity profile.
Open questions
- Long-term use: no meaningful data exist on months or years of continuous administration in any population.
- Kidney function: since the drug is cleared renally, impaired kidney function would be expected to slow its elimination — relevant given the elderly PK data.
- Combinations: there is a published case report of slow heart rate (bradycardia) after an overdose involving a very large amount of the GABAergic substance phenibut combined with fasoracetam. This does not establish causation by fasoracetam, but it underscores that combining GABA-active or cardiovascular-active substances is uncharted territory.
- Pregnancy and breastfeeding: animal data show substantial fetal and milk transfer; no human safety data exist.
- Interactions: largely unknown. Because fasoracetam influences GABA and acetylcholine signaling, theoretical additive effects with sedatives, alcohol, GABAergic drugs, or cholinergic drugs cannot be excluded.
Chemical Informations
| CAS Number: | 110958-19-5 |
|---|---|
| Purity: | ≥98% |
| Molecular Weight: | 196.25 g/mol |
| Melting Point: | + 57 °C |
| Molecular Formula: | C10H16N2O2 |
| Synonyms: | (5R)-5-oxo-D-prolinepiperidinamide monohydrate, NS-105, AEVI-001, LAM 105, MDGN-001, NFC 1, N-(5-Oxo-D-prolyl)piperidine, UNII-42O8UF5CJB, (R)-1-((5-Oxo-2-pyrrolidinyl)carbonyl)piperidine |
| PubChem CID: | 198695 |
| SMILES: | C1CCN(CC1)C(=O)C2CCC(=O)N2 |
Technical Information:
| Application | Metabotropic Glutamate Receptor Agonist |
| CAS | 110958-19-5 |
| Molar Mass | 196.25 g/mol |
| Chemical Formula | C10H16N2O2 |
| IUPAC Name | (5R)-5-(piperidine-1-carbonyl)pyrrolidin-2-one |
| Synonyms | 5-oxo-D-prolinepiperidinamide monohydrate, NS 105, NS-105, Fasoracetam [INN], NS 105 (pharmaceutical), N-(5-Oxo-D-prolyl)piperidine, UNII-42O8UF5CJB, NS-105, (R)-1-((5-Oxo-2-pyrrolidinyl)carbonyl)piperidine, 42O8UF5CJB, NCGC00182992-01, LAM-105, Piperidine, 1-((5-oxo-2-pyrrolidinyl)carbonyl)-, (R)-, (r)-1-[(5-oxo-2-pyrrolidinyl)carbonyl]piperidine, (+)-1-(((R)-5-Oxo-2-pyrrolidinyl)carbonyl)piperidine, D07WHN, AC1L55VI, DSSTox_CID_28781, DSSTox_RID_83050, CAS-110958-19-5, LS-115850, C13311 |
| Storage | Store at room temperature. Keep tightly sealed, away from heat, light and moisture. |
| Solubility | Soluble in PEG400 |
| Organoleptic Profile | Clear liquid |
| Physical Form | Liquid, solved in PEG400 |
| Specification | 25mg/mL ± 10% |
